between low-grade inflammation and specific psychotic symptoms has not been examined.
PRENATAL INFECTION AND LONG-TERM BRAIN PATHOLOGY: FROM PRECLINICAL MODELS TO MECHANISMS
Juliet Richetto* ,1
University of Zurich
Background: Prenatal exposure to infection is increasingly recognized to play an important etiological role in neuropsychiatric and neurological disorders with neurodevelopmental components, including schizophrenia, autism, bipolar disorder, and mental retardation. The adverse effects induced by prenatal infection may reflect an early entry into a deviant neurodevelopmental route, but the specificity of subsequent disease or symptoms is likely to be influenced by the genetic and environmental context in which the prenatal infectious process occurs. The epidemiological link between prenatal infection and increased risk of neurodevelopmental disorders also receives strong support from experimental work in animal models. These models are based on maternal gestational exposure to specific infectious agents such as influenza virus or immune activating agents such as the bacterial endotoxin lipopolysaccharide (LPS) or the viral mimic poly(I:C). Methods: Converging evidence form these models suggests that prenatal immune activation can negatively affect early foetal brain development and change the offspring's neurodevelopmental trajectories, which in turn can lead to the emergence of behavioral and cognitive disturbances in later life. Modelling the human epidemiological association between prenatal infection and increased risk of neurodevelopmental disorders in animals has also greatly advanced our understanding of the underlying mechanisms. According to the prevailing view, cytokine-associated inflammatory events, together with downstream pathophysiological effects such as oxidative stress and (temporary) macronutrient and micronutrient deficiency, seem critical in mediating the post-acute effects of maternal infection on the foetal system. Results: Recent findings have further implicated epigenetic processes as possible molecular mechanisms translating the negative effects of prenatal immune activation on the offspring. Not only does prenatal immune activation cause long-lasting epigenetic modifications such as altered DNA methylation and miRNA expression, but it also causes a transgenerational transmission of behavioral and neuronal abnormalities without additional immune exposures. Discussion: Prenatal infection and associated developmental neuroinflammation may have a pathological role in shaping neurodevelopmental disease risk across generations.
OPTIMISE-ING THE TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA Celso Arango Hospital General Universitario Gregorio Marañon
Overall Abstract: Even if there have been effective antipsychotic treatments for more than fifty years, the implementation of these treatments in clinical practice is still far from optimal, and a significant amount of patients with schizophrenia show poor outcomes. It is unquestionable that antipsychotics remain the first treatment option for patients with first-episode schizophrenia (FES). However, several questions still demand answer in the field. It is unclear how long we should wait before changing an antipsychotic that has not been fully effective, how long we have to wait before starting clozapine in FES, whether we can identify who will respond better to current treatments using biological markers including neuroimaging, and how to improve adherence and functional prognosis after clinical remission is achieved.
OPTiMiSE ('Optimisation of Treatment and Management of Schizophrenia in Europe') is an European Consortium funded under the VII Framework
Program that addressed these questions in a sample of nearly 500 patients with FES or schizophreniform psychosis and minimal prior exposure to antipsychotics recruited across Europe and Israel. Within an integrative framework, the Consortium aimed at combining clinical, neuroimaging, genetic and biochemical data in a large representative sample to provide answers to these clinically relevant questions and prepare the field for personalised medication strategies as drugs with novel mechanisms of action become available. Results from this study have not yet been published and most of them will be presented for the first time in a Congress. Based on previous results from the EUFEST study, all patients received amisulpride as a first step. For those not achieving remission after 4 weeks, OPTiMiSE compared in a randomised double-blind fashion the option of staying on amisulpride or moving to a drug with a different receptorbinding profile, olanzapine. In those not achieving remission after 6 weeks, clozapine was started. OPTiMiSE thus constitutes the first systematic, large-scale testing of the potential benefits of early switching to an antipsychotic with different characteristics in patients not achieving remission, and the application of clozapine in non-remitting patients within the first 10 weeks of treatment. OPTiMiSE also provides information on the added value of psychosocial interventions to improve treatment adherence, reduce relapses and improve functional outcomes after remission is achieved, through a 1-year follow-up randomised controlled trial testing a web-based program comprising a motivational intervention package, psychoeducation, and electronic medication alerts and updates. OPTiMiSE also collected blood samples for patients participating in the clinical trial and a systematic sample of more than 200 standardised, high-quality, magnetic resonance imaging (MRI) images. Based on this information, OPTiMiSE examined the clinical utility and cost-effectiveness of MRI for screening of underlying organic conditions in FES. In addition, OPTiMiSE also offers novel information on how MRI alterations, genetic and biochemical markers at first presentation of schizophrenia can predict the response to subsequent treatment. For this, OPTiMiSE used two broad strategies-a combination of technologydriven (pharmacogenetics, proteomics, and metabolomics) and hypothesisdriven (neuroimaging, neurochemical, and immune-related) markers. This symposium offers an overview of the main results obtained in the project in all these areas, with special focus on their clinical and research implications.
